Is Lexaria Bioscience Corp (LEXXW) overvalued? · rev $705.9K
Lexaria Bioscience Corp (LEXXW) common stock listed on US.
This page asks whether Lexaria Bioscience Corp (LEXXW) looks expensive on cached numbers — not a short thesis.
Latest reported LEXXW revenue for 2025-08-31 was $705.9K. Net income was -$11.9M. Revenue was up 52.0% from 2024-08-31 to 2025-08-31. LEXXW currently screens at market cap $33.8M.
LEXXW currently screens at market cap $33.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LEXXW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LEXXW stock page for the full model, not this heading.
Not investment advice.